ArticleJournal of clinical lipidology
Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes.
Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 11 citations in OpenAlex.
- Whole-exome sequencing in maya indigenous families: variant in PPP1R3A is associated with type 2 diabetes.Molecular genetics and genomics : MGG · 2018Article
- Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.Journal of lipids · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBecause type 2 diabetes (T2D) is a coronary artery disease risk equivalent, it is important to identify difference in risk markers between cases with T2D and the metabolic syndrome (MetS) compared with those with MetS alone. We evaluated apolipoproteins as possible distinguishing markers in the Oklahoma Cherokee.
objectiveTo assess apolipoproteins (apo) A-I, B, and C-III in young adult Cherokee who have the metabolic syndrome (MetS), as defined by the National Cholesterol Education Program (NCEP), either with or without T2D.
methodsA cross-sectional comparison of young adult Oklahoma Cherokee, ages 18 to 40 years, was conducted to assess differences in the apolipoproteins caused by the presence or absence of T2D among those with MetS, after we adjusted for age and gender.
resultsApoA-I (P = .0222) and high-density lipoprotein cholesterol (HDL-C; P = .0364) were lower, and apoB (P = .0106) and the apoB to A-I ratio (P < .0001) were greater in participants with the MetS and T2D than in those with MetS but without T2D. However, cholesterol, triglyceride, low-density lipoprotein cholesterol, non-HDL-C, total apoC-III, non-HDL apoC-III and the bimodal lipoprotein distribution of apoC-III (apoC-III ratio) were not significantly different between the two groups.
conclusionApoA-I and HDL-C are lower and apoB and the apoB:A-I ratio are greater in those with MetS and T2D than in those who have the MetS but without T2D, suggesting that the presence of diabetes adversely influences plasma apoA-I and apoB levels. However, apoC-III and non-HDL apoC-III are unchanged by the addition of diabetes suggesting that the increased levels associated with MetS may precede T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.